menu
    • menu
    [{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STMC-103H","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Nexilico","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Microbial-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Siolta Therapeutics \/ Siolta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Siolta Therapeutics \/ Siolta Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Siolta Therapeutics

    Menu

    Siolta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Microbial-based Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Recipient : Nexilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nexilico and Siolta Partner On Microbiome Drug For Necrotizing Enterocolitis

                            Details : The collaboration combines Nexilico's AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for the treatment approaches in infant health.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Microbial-based Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Recipient : Nexilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : SymBiosis and Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

                            Details : The financing aims to support the advancement of the Siolta clinical program STMC-103H, which is being evaluated in Phase I/II clinical trial studies for Atopic Dermatitis and Type 1 Hypersensitivity.

                            Brand Name : STMC-103H

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : SymBiosis and Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-I...

                            Details : STMC-103H is a Live Biotherapeutic Product (LBP) for the prevention and treatment of atopic diseases (atopic dermatitis, atopic asthma, food allergy, allergic rhinitis) in at-risk newborns based on an immediate family history of atopic diseases.

                            Brand Name : STMC-103H

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 20, 2022

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Awarded NIH Grant

                            Details : The grant will provide funding for the continued development and optimization of manufacturing approaches for live biotherapeutic products containing strictly anaerobic, non-spore forming bacteria as active pharmaceutical ingredients including STMC-103H.

                            Brand Name : STMC-103H

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Siolta Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

                            Details : The latest round of capital will go towards supporting clinical proof of concept (POC) trials testing the efficacy of their lead LBP product, STMC-103H.

                            Brand Name : STMC-103H

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : STMC-103H

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth